GoodRx (GDRX)
(Delayed Data from NSDQ)
$8.97 USD
+0.06 (0.67%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $8.98 +0.01 (0.11%) 4:18 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.97 USD
+0.06 (0.67%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $8.98 +0.01 (0.11%) 4:18 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
GoodRx Holdings, Inc. (GDRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc's (TDOC) BetterHelp Faces FTC Hurdle, to Pay $7.8M
by Zacks Equity Research
Teladoc's (TDOC) BetterHelp business is expected to continue implementing more comprehensive privacy standards.
GoodRx Holdings, Inc. (GDRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 40% and 3.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -33.33% and 2.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Life Time Group Holdings, Inc. (LTH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Think GoodRx Holdings, Inc. (GDRX) Could Surge 97%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 97.4% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GDRX or LHCG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GDRX vs. LHCG: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 75% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.
Earnings Preview: Agiliti (AGTI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Agiliti (AGTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ModivCare (MODV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 6.62% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.
AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.
GoodRx Holdings, Inc. (GDRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why GoodRx Holdings, Inc. (GDRX) Could Beat Earnings Estimates Again
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.
Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.
Here's Why GoodRx Holdings, Inc. (GDRX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.